Hematology-Oncology Division, Department of Women's and Children's Health, Padova University Hospital, Padua, Italy.
Department of Pediatric Surgery, Hôpital Necker-Enfants Malades, Université de Paris, Paris, France.
Pediatr Blood Cancer. 2021 Jun;68 Suppl 4(Suppl 4):e29045. doi: 10.1002/pbc.29045. Epub 2021 Apr 7.
Pleuropulmonary blastoma (PPB) is a rare cancer occurring mainly during early childhood and often associated with germline DICER1 mutations. It is classified by the macroscopic appearance into three interrelated clinico-pathologic entities on a developmental continuum. Complete tumor resection is a main prognostic factor and can be performed at diagnosis or after neoadjuvant treatment that includes chemotherapy and in some cases radiotherapy. Optimal modalities of neo- or adjuvant treatments can be challenging taking into account potential long-term toxicities in this young population. This paper presents the recommendations for diagnosis and treatment of children and adolescents with PPB elaborated by the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) within the European Union-funded project PARTNER (Paediatric Rare Tumours Network - European Registry).
肺胸膜胚细胞瘤(PPB)是一种罕见的癌症,主要发生在儿童早期,常与种系 DICER1 突变有关。它根据宏观外观在发育连续体上分为三种相互关联的临床病理实体。完全肿瘤切除是主要的预后因素,可以在诊断时或在新辅助治疗后进行,新辅助治疗包括化疗,在某些情况下还包括放疗。在考虑到这一年轻人群中潜在的长期毒性的情况下,新辅助或辅助治疗的最佳方式可能具有挑战性。本文介绍了由欧盟资助的 PARTNER 项目(儿科罕见肿瘤网络-欧洲登记处)中的欧洲儿科罕见肿瘤合作研究组(EXPeRT)制定的用于诊断和治疗儿童和青少年 PPB 的建议。